Abigail Hitchens

RTI Health Solutions — United States

Medicine · Health Sciences

4h-index55citations29works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(12), BRCA gene mutations in cancer(6), PARP inhibition in cancer therapy(6), Hepatocellular Carcinoma Treatment and Prognosis(5), Breast Cancer Treatment Studies(4)

Publications29 total

Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US
Blood·2025Open Access
Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2− advanced breast cancer in Europe
Breast Cancer Research and Treatment·2025· 1 citedOpen Access
Prevalence of health conditions associated with higher risk for severe respiratory syncytial virus, influenza, or COVID-19
Current Medical Research and Opinion·2025
Real-world (RW) outcomes of patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) receiving first-line (1L) luspatercept (LUSPA) or 1L erythropoiesis-stimulating agents (ESA) in the US.
Journal of Clinical Oncology·2025
211P Risk of recurrence (ROR) among patients (pts) with HR+/HER2− early breast cancer (EBC) involving 1-3 axillary lymph nodes (N1): A real-world evaluation
ESMO Open·2025Open Access
Real‐world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X‐linked protoporphyria
The Journal of Dermatology·2025· 2 citedOpen Access
COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record Review
Neurology and Therapy·2024· 1 citedOpen Access
Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US.
Journal of Clinical Oncology·2024
Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States
Frontiers in Oncology·2024Open Access
903. Prevalence of Underlying Conditions Associated With Higher Risk for Severe RSV, Influenza, or COVID-19 in Adults in the United States, 2017-2018
Open Forum Infectious Diseases·2023· 3 citedOpen Access
EE522 Healthcare Resource Use and Costs Among Patients with Erythropoietic Protoporphyria and X-Linked Protoporphyria in the United States
Value in Health·2023Open Access
213P Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe
ESMO Open·2023· 1 citedOpen Access
222P Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER)
ESMO Open·2023Open Access
Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review
Clinical Genitourinary Cancer·2023· 7 cited
Recent Trends in Hypoparathyroidism-Related Inpatient and Emergency Department Admissions and Costs in the United States
Journal of the Endocrine Society·2023· 3 citedOpen Access
<scp>Real‐world</scp> effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in <scp>US</scp> clinical practice
Cancer Reports·2022· 5 citedOpen Access
HSD95 Real-World Treatment Patterns and Healthcare Resource Utilization Among Patients Diagnosed with Erythropoietic Protoporphyria and X-Linked Protoporphyria: Results from a US Electronic Medical Records Study
Value in Health·2022
Abstract P2-09-08: Impact of race on clinical outcomes among patients with advanced triple negative breast cancer (TNBC) and Germline <i>BRCA1/2</i> mutation(s) (g<i>BRCA1/2</i>mut): Results from a US real-world study
Cancer Research·2022
Abstract P1-18-18: Real-world natural history data among patients with <i>PIK3CA</i>-mutant and <i>PIK3CA</i>-wild-type advanced breast cancer
Cancer Research·2022· 1 cited
Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis
Clinical Gastroenterology and Hepatology·2021· 5 cited
page 1 of 2Next →

Frequent Co-authors

Rohan Parikh(16), Elizabeth Esterberg(10), Keith L. Davis(8), Alexander Niyazov(7), Bhakti Arondekar(7), Lillian Shahied Arruda(7), Elias Obeid(7), Amit G. Singal(5), Saurabh Nagar(5), Shrividya Iyer(5), Sean D. Candrilli(5), Katherine Houghton(4), Valérie Derrien Ansquer(4), Malgorzata Ciepielewska(3), Pedram Razavi(3), Anton Safonov(3), Jane Chang(2), Mairead Kearney(2), Mayank Ajmera(2), Parinaz Ghaswalla(2)